Hunter is co-founder and Executive Chairman of Navigen. He was a co-founder and served as Chairman and CEO of NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) from 1986 to 2006. Three products were brought forward during Hunter's tenure at NPS. The first product, Sensipar®, was launched in 2004 for the treatment of secondary hyperparathyroidism and hypercalcemia. It is marketed by Amgen in the U.S. and Europe and by Kyowa Hakko Kirin in Asia, and generated sales of over $1 billion in 2012. NPS’s second product, Natpara®, an injectable synthetic hormone approved for treatment of hypoparathyroidism, is marketed by Shire. The company's third product, Gattex®, an injectable peptide for the treatment of short bowel syndrome, was launched worldwide in 2013. Under Hunter's leadership at NPS, the company entered into major agreements with Pfizer, FMC, GlaxoSmithKline, Amgen, Kirin, Abbott, AstraZeneca, Allergan, and Nycomed. Additionally, the company raised approximately $900 million dollars through public and private financings.
Hunter was a member of the Governing Authority of the Utah Science, Technology, and Research Economic Development Initiative (USTAR) from 2006-2012 and received the 1998 Ernst & Young Utah Entrepreneur of the Year Award and the 2002 Utah Governor's Medal for Science and Technology.
Hunter has a BA in American Literature from the University of Illinois, a PhD in Psychobiology from Yale University and did his postdoctoral work in the Neurosurgery Department at the University of Virginia Medical Center.
ABOUT NAVIGENCreating a New Class of Drugs
Navigen is a drug discovery and development company developing an important new class of therapies to improve and save lives. The company was founded by a team of industry veterans with a history of successfully advancing novel therapeutics. Navigen is leveraging its unparalleled experience working with D-peptides to bring forward a range of promising development programs with the potential to address many critical areas of unmet medical need.
Building on landmark discoveries made at leading medical research institutions including the University of Utah, we have developed a discovery platform that harnesses the full potential of D-peptides as drugs with superior targeting and specificity and with limited or no risk of antigenicity. Navigen has a suite of proprietary tools at its disposal to access more (larger) targets and to shorten the required time it takes to identify promising new drugs.
Our lead products are targeting critical areas of unmet need including treatment and prevention of HIV and respiratory syncytial virus (RSV). We are also developing a D-peptide anti-TNF that we expect to have significant delivery and antigenicity advantages over current biologics.
We will continue to build our internal pipeline and will also enter into collaborations to discover new D-peptides for targets of interest.
We welcome inquiries related to partnering including R&D collaborations and licensing.
Our PeopleMeet the Navigen Team
Navigen Executive Chairman Hunter Jackson, PhD, CEO Brandi Simpson, MBA, Vice President of Research Alan Mueller, PhD, and Sr. Director of Pre-Clinical Development Daniel Wettstein, MD, PhD have over 90 years of combined experience in bringing forward biomedical technologies in both private and public company settings.